![Cover Image for [Webinar] Optimizing Cetuximab: How Cradle’s 12 designs would have ranked top-12 in Adaptyv’s protein design competition](https://images.lumacdn.com/cdn-cgi/image/format=auto,fit=cover,dpr=2,background=white,quality=75,width=400,height=400/event-covers/z2/84414320-2668-45e7-b740-16ec36f6aecd.png)
[Webinar] Optimizing Cetuximab: How Cradle’s 12 designs would have ranked top-12 in Adaptyv’s protein design competition
We won Adaptyv's protein design competition in December with an AI-generated antibody variant against EGFR. The winning design achieved 8x stronger binding than the commercial benchmark, Cetuximab.
After in-vitro validation of binding and expression we learned all 12 of our designs would have taken position 1-12 in the competition. Three even achieved sub-nanomolar binding, outperforming our original competition winner.
In this webinar, we'll show how Cradle's zero-shot diversification approach outperformed state-of-the-art de novo protein design methods by strategically optimizing an existing therapeutic antibody. Learn how our platform identified key framework mutations while preserving CDRs, resulting in multiple sub-nanomolar binders with improved expression and maintained developability profiles.
Agenda
Platform Overview: Understanding Cradle's approach to protein engineering and how it differs from traditional methods
Live Case Study: See a technical walkthrough of how we optimized Cetuximab with just one click
Results & Validation: We’ll explore the experimental data and the competition
Future Applications & outlook
Q&A Session: Get your questions answered by the Cradle team
Speakers
Elise de Reus – Co-Founder, Partnerships @ Cradle
Constance Ferragu - Machine Learning Engineer @ Cradle
Date
Wednesday, April 16th, 2025 | 16:00-17:00 CET / 10:00-11:00 AM EDT
Who this event is for
This webinar will be especially interesting for
Protein engineers and scientists working in therapeutic antibody development
Biopharma R&D teams interested in optimization approaches for existing therapeutics
Computational biologists exploring AI applications in protein engineering
Drug discovery researchers looking for more efficient ways to improve binding affinity
Biotech executives evaluating new technologies for their R&D pipelines
Register now via lu.ma or Linkedin events. The event will be streamed live via Linkedin.